Abstract
There is an urgent need for inexpensive, rapid and specific antigen-based assays to test for infection with SARS-CoV-2 and distinguish variants arising as the COVID-19 pandemic spreads. We have identified a small, synthetic protein (JS7), representing a region of maximum variability within the receptor binding domain (RBD), which binds antibodies in sera from nine patients with PCR-verified COVID-19 of varying severity. Antibodies binding to either JS7 or the SARS-CoV-2 recombinant RBD, as well as those that disrupt binding between a fragment of the ACE2 receptor and the RBD, are proportional to disease severity and clinical outcome. Binding to JS7 was inhibited by linear peptides from the RBD interface with ACE2. Variants of JS7, such as N501Y, can be quickly synthesized in a pure form in large quantities by automated methods. JS7 and related synthetic antigens can provide a basis for specific diagnostics for SARS-CoV-2 infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Peptide and protein syntheses at LANL were supported by LDRD ER funding. NETEC and SPRN are funded by the US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), CFDA #93.825.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human sera after infection with COVID-19 were obtained from the tissue bank at UTMB. The 10 samples from 9 patients (Table S1) were negative for residual virus presence. De-identified clinical samples and clinical data were collected from consented patients under the Observational Protocol for Diseases and Exposures of Public Health Importance (UNMC IRB # 060-20-EP/UTMB-IRB # 20-0031), PI, Dr. Mark Kortepeter, U. Nebraska Medical Center; UTMB site-PI, Dr. Susan McLellan, developed by the Special Pathogens Research Network (SPRN) of the National Emerging and Special Pathogens Training and Education Center (NETEC). NETEC and SPRN are funded by the US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), CFDA #93.825. 1)Five control sera (from normal individuals) were collected in the US in April of 2019 (Table S2) with informed consent under Colorado Multiple Institution Review Board (COMIRB) 00-802, Redefining the Major Peanut Allergens. All samples are de-identified.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is either included in the paper, supplementary material, or available from the authors
